What is the price target for RARE stock?
27 analysts have analysed RARE and the average price target is 57.68 USD. This implies a price increase of 170.3% is expected in the next year compared to the current price of 21.34.
ULTRAGENYX PHARMACEUTICAL IN (RARE) Forecast, Price Target & Analyst Ratings
NASDAQ:RARE • US90400D1081
Current stock price
21.34 USD
-0.37 (-1.7%)
At close:
21.3348 USD
-0.01 (-0.02%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ULTRAGENYX PHARMACEUTICAL IN (RARE).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.51
- Revenue Estimate
- 166.57M
Price Target Details & History
Consensus Price Target and Range
Mean target
$57.68
Upside
+ 170.30%
From current price of $21.34 to mean target of $57.68, Based on 27 analyst forecasts
Low
$25.25
Median
$51.51
High
$126.00
Price Target Revisions
1 Month
-13.73%
3 Months
-31.12%
Price Target Summary
27 Wall Street analysts provided a forecast for the next 12 months for RARE. The average price target is 57.68 USD. This implies a price increase of 170.3% is expected in the next year compared to the current price of 21.34.
The average price target has been revised downward by 31.12% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.19%
RARE was analyzed by 27 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about RARE.
In the previous month the buy percentage consensus was at a similar level.
RARE was analyzed by 27 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-12 | JP Morgan | Maintains | Overweight -> Overweight |
| 2026-02-18 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-18 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-02-17 | Wedbush | Reiterate | Neutral -> Neutral |
| 2026-02-17 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2026-02-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-02-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-01-05 | Guggenheim | Maintains | Buy -> Buy |
| 2026-01-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-02 | B of A Securities | Maintains | Buy -> Buy |
| 2025-12-30 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-12-30 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-12-30 | Baird | Maintains | Outperform -> Outperform |
| 2025-12-30 | Jefferies | Maintains | Buy -> Buy |
| 2025-11-24 | Barclays | Maintains | Overweight -> Overweight |
| 2025-11-05 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-05 | Truist Securities | Maintains | Buy -> Buy |
| 2025-09-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-05 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-08-08 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2025-08-06 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-07-14 | Wedbush | Maintains | Neutral -> Neutral |
| 2025-07-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-10 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-06-20 | Guggenheim | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$1.51
- Revenue Estimate
- 166.57M
- Revenue Q2Q
- 19.58%
- EPS Q2Q
- 3.98%
- Number of Analysts
- 21
Next Earnings Revisions
Revenue (1 Month)
-4.71%
Revenue (3 Months)
-4.82%
EPS (1 Month)
5.90%
EPS (3 Months)
6.72%
Next Earnings Summary
RARE is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -1.51 USD and the consensus revenue estimate is 166.57M USD.
The next earnings revenue estimate has been revised downward by 4.82% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 434.249M 19.53% | 560.23M 29.01% | 673M 20.13% | 763.16M 13.40% | 1.09B 42.83% | 1.348B 23.67% | 1.754B 30.12% | 2.266B 29.19% | 2.489B 9.84% | 2.931B 17.76% | 3.398B 15.93% | |
| EBITDA YoY % growth | -543.202M 13.87% | -500.43M 7.87% | -500M 0.09% | -422.147M 15.57% | 9.526M 102.26% | 43.547M 357.14% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -569.208M 12.28% | -535.973M 5.84% | -535M 0.18% | -443.941M 17.02% | -24.016M 94.59% | 126.86M 628.22% | 450.6M 255.19% | 775.59M 72.12% | 926.8M 19.50% | 1.135B 22.46% | 1.379B 21.50% | |
| Operating Margin | -131.08% | -95.67% | -79.49% | -58.17% | -2.20% | 9.41% | 25.69% | 34.23% | 37.24% | 38.72% | 40.58% | |
| EPS YoY % growth | -8.33 17.61% | -6.34 23.89% | -5.84 7.89% | -4.44 24.05% | -0.77 82.59% | 0.94 221.35% | 3.85 310.46% | 6.62 72.03% | 8.66 30.79% | 10.85 25.38% | 11.11 2.40% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.51 3.98% | -1.26 -7.27% | -1.11 38.52% | -0.73 43.57% | -0.94 37.75% | -0.23 81.31% | 0.06 105.50% | 0.67 192.48% |
| Revenue Q2Q % growth | 166.57M 19.58% | 185.69M 11.53% | 200.23M 25.20% | 234.81M 13.43% | 213.48M 28.16% | 278.32M 49.88% | 311.54M 55.59% | 389.47M 65.87% |
| EBITDA Q2Q % growth | -113.647M 15.16% | -98.52M -9.13% | -94.626M 34.59% | -101.325M -29.43% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -141.309M 1.14% | -115.829M -7.36% | -104.008M 39.14% | -95.236M 15.93% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
29.28%
EPS Next 5 Year
25.66%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
25.91%
Revenue Next 5 Year
27.39%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
27.70%
EBIT Next 5 Year
N/A
ULTRAGENYX PHARMACEUTICAL IN / RARE Forecast FAQ
Can you provide the upcoming earnings date for ULTRAGENYX PHARMACEUTICAL IN?
ULTRAGENYX PHARMACEUTICAL IN (RARE) will report earnings on 2026-05-04.
What are the consensus estimates for ULTRAGENYX PHARMACEUTICAL IN (RARE) next earnings?
The consensus EPS estimate for the next earnings of ULTRAGENYX PHARMACEUTICAL IN (RARE) is -1.51 USD and the consensus revenue estimate is 166.57M USD.
How do analysts rate ULTRAGENYX PHARMACEUTICAL IN (RARE)?
The consensus rating for ULTRAGENYX PHARMACEUTICAL IN (RARE) is 85.1852 / 100 . This indicates that analysts generally have a positive outlook on the stock.